Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.351 EUR | -1.13% | -2.50% | -10.00% |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Dec. 05 | Celyad Oncology CEO Resigns | MT |
Sales 2021 | - | Sales 2022 | - | Capitalization | 11.43M 12.32M |
---|---|---|---|---|---|
Net income 2021 | -26M -28.02M | Net income 2022 | -40M -43.11M | EV / Sales 2021 | - |
Net cash position 2021 | 27.39M 29.51M | Net cash position 2022 | 12.19M 13.14M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.07
x | P/E ratio 2022 |
-0.28
x | Employees | 37 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 92.37% |
Latest transcript on Celyad Oncology SA
1 day | -1.13% | ||
1 week | -2.50% | ||
Current month | -7.87% | ||
1 month | -6.65% | ||
3 months | -8.59% | ||
6 months | -45.16% | ||
Current year | -10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.351 | -1.13% | 8,209 |
24-03-27 | 0.355 | 0.00% | 3,795 |
24-03-26 | 0.355 | +1.43% | 4,889 |
24-03-25 | 0.35 | -1.41% | 5,865 |
24-03-22 | 0.355 | -1.39% | 8,769 |
Real-time Euronext Bruxelles, March 28, 2024 at 12:35 pm EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.00% | 15.71M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |